Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695391 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL30978010 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL10853940 | 0.94 | MAPT (0.89) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL10853946 | 0.94 | MAPT (0.89) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL10847571 | 0.89 | MAPT (0.81) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL10847566 | 0.89 | MAPT (0.81) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL5695418 | 0.86 | MAPT (0.76) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL5695424 | 0.86 | MAPT (0.76) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL5695395 | 0.86 | MAPT (0.76) | MAPTMEN1KMT2AHPGDHTT | |
| SCHEMBL5695393 | 0.86 | MAPT (0.76) | MAPTMEN1KMT2AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300135-B1 | Agent for dyeing keratinous fibres comprising 2-aryliden-indolin-3-one derivatives | HENKEL KGAA (DE) | 2006-05-03 | — | — | EP | claimed |
| CN-116162052-B | Preparation method of 2-benzylidene indoline-3-ketone compound | 三峡大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11286245-B2 | Therapeutic aurones | Middle Tennessee State University (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210053933-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053933-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2021-02-25 | — | — | US | disclosed |
| US-10899727-B2 | Therapeutic aurones | Middle Tennessee State University (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200399238-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399238-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020223439-A1 | AURONES AND METHODS OF USING AURONES TO TREAT TUBERCULOSIS | Middle Tennessee State University (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20190169151-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190169151-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3442520-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017180644-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899727-B2 | Therapeutic aurones | AURKA, PIGS, PRF1 | MAPT 3325/4885MEN1 2702/4885KMT2A 2551/4885 |
| US-20200399238-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | MAPT 3325/4885MEN1 2702/4885KMT2A 2551/4885 |
| US-11286245-B2 | Therapeutic aurones | AURKA, PIGS, PRF1 | MAPT 3325/4885MEN1 2702/4885KMT2A 2551/4885 |
| US-20210053933-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | MAPT 3325/4885MEN1 2702/4885KMT2A 2551/4885 |
| US-20190169151-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | MAPT 3325/4885MEN1 2702/4885KMT2A 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.